Gene · 1859
DYRK1A: dual specificity tyrosine phosphorylation regulated kinase 1A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. DYRK1A: dual specificity tyrosine phosphorylation regulated kinase 1A. Genes, record 1859. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1859
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13627 | Dual specificity tyrosine-phosphorylation-regulated kinase 1A | 763 | 92 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4727938 A1 | 2026-04-22 | 1 | Q13627 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 44351 | Q13627 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 6280 | Q13627 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 6280 | Q13627 | Espacenet |
| WO 2024259116 A1 | 2024-12-19 | 1 | Q13627 | Espacenet |
| WO 2024259121 A1 | 2024-12-19 | 1 | Q13627 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 136 | Q13627 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 25833 | Q13627 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 128804 | Q13627 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 3343 | Q13627 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| LORECIVIVINT | CHEMBL4297639 | Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor | INHIBITOR |
Source ChEMBL
Trials11
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT05603754 | LORECIVIVINT | PHASE3 | ClinicalTrials.gov | |
| NCT04931667 | LORECIVIVINT | PHASE3 | ClinicalTrials.gov | |
| NCT04520607 | LORECIVIVINT | PHASE3 | ClinicalTrials.gov | |
| NCT04385303 | LORECIVIVINT | PHASE3 | 2026-02-04 | ClinicalTrials.gov |
| NCT03928184 | LORECIVIVINT | PHASE3 | 2026-02-13 | ClinicalTrials.gov |
| NCT03727022 | LORECIVIVINT | PHASE2 | 2026-01-12 | ClinicalTrials.gov |
| NCT03706521 | LORECIVIVINT | PHASE2 | 2026-03-04 | ClinicalTrials.gov |
| NCT03246399 | LORECIVIVINT | PHASE1 | ClinicalTrials.gov | |
| NCT03122860 | LORECIVIVINT | PHASE2 | 2021-05-18 | ClinicalTrials.gov |
| NCT02536833 | LORECIVIVINT | PHASE2 | 2020-09-16 | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsNIH grants2,474
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | DYRK1A papers | Newest fiscal year |
|---|---|---|---|
| R01MH101221 | Rare Mutations and Autism Spectrum Disorders | 32 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 7 | 2025 |
| T32HG000035 | Interdisciplinary Training in Genome Sciences | 6 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 5 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 5 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 2,474Source NIH's project files
See all 2,474 nih grantsPapers3,825
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Genetic architecture and molecular pathogenesis of Parkinson's disease: emerging mechanisms and therapeutic targets. | Metab Brain Dis | 2026 | 42803978 | PubTator, text mining | PubMed |
| Targeting DYRK1A with rationally designed pyrazine-guanidine hybrids for Alzheimer's disease: design, synthesis, and biological evaluation. | RSC Adv | 2026 | 42780659 | PubTator, text mining | PubMed |
| Harmine selectively enhances human beta cell identity markers and function via protein kinase A pathways. | Diabetologia | 2026 | 42766004 | PubTator, text mining | PubMed |
| Network modeling predicts how DYRK1A inhibition promotes cardiomyocyte cycling after ischemia/reperfusion injury. | JCI Insight | 2026 | 42752366 | PubTator, text mining | PubMed |
| DYRK kinases phosphorylate IL-17RA at S801. | Serican J Med | 2026 | 42746556 | PubTator, text mining | PubMed |
| Baseline cellular state shapes the molecular impact of mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) alleles in reconstituted pancreatic cancer cells. | Mol Omics | 2026 | 42720273 | PubTator, text mining | PubMed |
| Amyloid precursor protein dosage normalization rescues neurogenesis and Alzheimer's Disease phenotypes associated with Down Syndrome. | Med Res Arch | 2026 | 42677302 | PubTator, text mining | PubMed |
| In silico structure-based design of superior DYRK1A enzyme inhibitors. | Comput Biol Chem | 2026 | 42673670 | PubTator, text mining | PubMed |
| Small-molecule DYRK1A Inhibitors for β-Cell Regeneration in Diabetes: Structural Insights and Medicinal Chemistry Advances. | Mini Rev Med Chem | 2026 | 42634309 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of quinazoline-carbazole derivatives as dual TXNIP/DYRK1A inhibitors for the treatment of type 2 diabetes mellitus. | Mol Divers | 2026 | 42631845 | PubTator, text mining | PubMed |
1 to 10 of 3,825
See all 3,825 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1859
GET https://conductscience.org/api/genes/v1/1859/patents?page=2